Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call
To participate in the call, please dial the following numbers:
888-506-0062 (toll-free) for Canadian and U.S. callers+1 973-528-0011 for international callers
Access code: 266173
A live webcast of the call will be available on the Investors section of Medexus's corporate website or at the following link:
https://www.webcaster4.com/Webcast/Page/2010/52642
A replay of the call will be available approximately one hour following the end of the call through Thursday, July 3, 2025. To access the replay, please dial the following numbers –
877-481-4010 for Canadian and U.S. callers+1 919-882-2331 for international callers
Conference ID: 52642
A replay of the webcast will be available on the Investors section of Medexus's corporate website until Friday, June 26, 2026.
About Medexus
Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology-oncology and allergy, dermatology, and rheumatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca.
Contacts
Ken d'Entremont | CEO, Medexus PharmaceuticalsTel: 905-676-0003 | Email: ken.dentremont@medexus.com
Brendon Buschman | CFO, Medexus PharmaceuticalsTel: 416-577-6216 | Email: brendon.buschman@medexus.com
Forward-looking statements
Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements). The words "anticipates", "believes", "expects", "will", "plans", "potential", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions, and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255789
Fehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Integra Resources Corp. (ITRG) Reports Strong Initial Results From 2025 Resource Growth Dilling Program in Nevada; H.C. Wainwright Maintains ‘Buy' Rating
Integra Resources Corp. (NYSE:ITRG) is one of the . A close-up of a technician using advanced geological-surveying equipment, evaluating a gold deposit. On August 5, 2025, Integra Resources Corp. (NYSE:ITRG) reported strong initial results from its 2025 resource growth drilling program at Florida Canyon Mine in Nevada. The program revealed broad, consistent near-surface oxide gold intercepts at the high-priority North Dump and Inter-Pit areas, with several exceeding current cut-off grades. Building on this momentum, the company expanded the program from 10,000 meters to 16,000 meters, aiming for accelerated resource growth and potential mine life extensions. Meanwhile, Integra Resources Corp. (NYSE:ITRG) reported Q2 2025 results on August 13, 2025. The mine recorded an output of 18,086 ounces of gold, meeting expectations and generating cash flow to support a planned $55 million reinvestment in Florida Canyon in 2025. Ahead of these developments, on July 18, 2025, H.C. Wainwright raised its price target to $3.25 from $2.75 with a 'Buy' rating. Integra Resources Corp. (NYSE:ITRG) is a growing precious metal producer in the Great Basin, Nevada, U.S. It is included in our list of the Best Penny Stocks. While we acknowledge the potential of ITRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Oil Refinery Stocks to Buy Right Now and 7 Best Potash Stocks to Buy According to Analysts. Disclosure: None. Sign in to access your portfolio
Yahoo
5 minutes ago
- Yahoo
Mizuho Reduces PT on PayPal Holdings, Inc. (PYPL)
With strong hedge fund interest and a low price-to-earnings ratio, PayPal Holdings, Inc. (NASDAQ:PYPL) secures a place on our list of the . Following the company's Q2 earnings release, Mizuho reduced its price target on PayPal Holdings, Inc. (NASDAQ:PYPL) from $87 to $84 on July 30, 2025. The analyst attributed the price revision to a slight dip in branded checkout growth and softer-than-expected transaction margin dollar guidance for the second half of 2025. Meanwhile, the company's core PayPal button business delivered strong performance when 'Buy Now Pay Later' and 'Pay with Venmo' segments are included. The latter segment is estimated to deliver 1.5 times the company-wide transaction margin. Furthermore, Barclays maintained its 'Buy' rating on PayPal Holdings, Inc. (NASDAQ:PYPL) on July 30 with a $90 target, and Needham maintained a 'Hold' rating the same day. Needham cited short-term e-commerce headwinds and modest EPS growth expectations. With its global technology platform, PayPal Holdings, Inc. (NASDAQ:PYPL) allows consumers to send, receive, and manage digital payments through multiple funding sources and channels. It is included in our list of the most undervalued value stocks to buy. While we acknowledge the potential of PYPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
5 minutes ago
- Yahoo
MVV Energie Third Quarter 2025 Earnings: EPS: €0.36 (vs €0.38 in 3Q 2024)
Explore MVV Energie's Fair Values from the Community and select yours MVV Energie (ETR:MVV1) Third Quarter 2025 Results Key Financial Results Revenue: €1.35b (up 3.4% from 3Q 2024). Net income: €23.7m (down 4.4% from 3Q 2024). Profit margin: 1.7% (down from 1.9% in 3Q 2024). The decrease in margin was driven by higher expenses. EPS: €0.36 (down from €0.38 in 3Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period MVV Energie's share price is broadly unchanged from a week ago. Risk Analysis Before we wrap up, we've discovered 2 warning signs for MVV Energie (1 is significant!) that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
